Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.

Details

Serval ID
serval:BIB_AE1EE9D0B706
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
Journal
Journal of Immunotherapy
Author(s)
Atkins M.B., Carbone D., Coukos G., Dhodapkar M., Ernstoff M.S., Finke J., Gajewski T.F., Gollob J., Lotze M.T., Storkus W., Weiner L.M.
ISSN
1524-9557 (Print)
ISSN-L
1524-9557
Publication state
Published
Issued date
2007
Volume
30
Number
6
Pages
577-590
Language
english
Notes
Publication types: Journal Article ; ReviewPublication Status: ppublish
Abstract
The International Society for Biologic Therapy of Cancer held a mini-symposium on October 26, 2006 in Los Angeles to review current information regarding the biologic effects of both standard and targeted therapies. The purpose of the mini-symposium was to describe the existing knowledge regarding various biologic effects of current therapies, identify the most relevant issues and gaps in the knowledge base and discuss the optimal means of obtaining necessary missing information. Topics discussed included: (1) The impact of antitumor monoclonal antibody therapy on antigen presentation and adaptive immunity; (2) the effects of antiangiogenic/targeted therapy of the immune system; (3) the impact of chemotherapy on angiogenesis and immune function; (4) combination of antiangiogenic and immunotherapy at the clinical level; (5) the effects of tyrosine kinase inhibitors on TH1/TH2 response and T-regulatory cells; (6) the impact of farnesyltransferase inhibitors and other targeted agents on T-cell activation; (7) the impact of epigenetic modulators on biologic properties, and (8) the impact of the nature of cell death on the immune system. The ultimate goals of this mini-symposium were to use the above information to inform and influence basic science efforts and discussions, rationally design combination treatment regimens and optimally employ correlative studies in the context of ongoing and future clinical investigations.
Keywords
Angiogenesis Inhibitors/therapeutic use, Antibodies, Monoclonal/immunology, Antibodies, Monoclonal/metabolism, Antineoplastic Agents/immunology, Antineoplastic Agents/metabolism, Apoptosis/immunology, Combined Modality Therapy, Humans, Immunologic Factors/immunology, Immunologic Factors/metabolism, Immunotherapy, Neoplasms/genetics, Neoplasms/immunology, Neovascularization, Pathologic
Pubmed
Web of science
Create date
14/10/2014 11:43
Last modification date
20/08/2019 15:17
Usage data